Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 7/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291275 | 0.84 | CYP1A2 (0.35) | IGF1RDRD2DRD4DRD3KMT2A | |
| SCHEMBL26547899 | 0.78 | KMT2A (0.36) | IGF1RDRD2DRD4DRD3KMT2A | |
| SCHEMBL18373037 | 0.75 | DRD2 (0.38) | DRD2DRD4DRD3KMT2A | |
| SCHEMBL23943060 | 0.73 | ESR1 (0.42) | IGF1RESR1ESR2HRH4ALPL | |
| SCHEMBL1106976 | 0.72 | CCNA2 (0.40) | IGF1R | |
| SCHEMBL20730399 | 0.70 | ESR1 (0.40) | ESR1KMT2AESR2 | |
| SCHEMBL21959665 | 0.70 | DRD2 (0.35) | DRD2DRD4DRD3KMT2A | |
| SCHEMBL23763330 | 0.69 | KMT2A (0.44) | DRD2DRD4DRD3KMT2AHRH4 | |
| SCHEMBL23943006 | 0.69 | ESR1 (0.39) | ESR1ESR2ALPL | |
| SCHEMBL5487500 | 0.69 | CDK2 (0.38) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | IGF1R 983/4885ESR1 3801/4885DRD2 4830/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | IGF1R 983/4885ESR1 3801/4885DRD2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.